Replies to post #210388 on Cytodyn Inc (CYDY)

[justdafactss]

Heres another laugh for baggies---

[RTBhub]

I agree, a merger or partnership may be announced soon.

What do you think the CYDY valuation will be in such a deal? I think it will be 60 cents.

[Monroe1]

AMEN, phrantic phallic phaillure on the phart of pig pharma loss of viagra coming up causing phuzzy Phizer weak stream as pps edges up on leronlimab stat sig ..... lot better than EUA vaxs and much better than "trending" renderdeathsevere while cries are heard phar and wide and phear is phelt phor what comes not phar away.

Stand by phor news.

That'll be the end zone football spike...standby

And CytoDyn doesn't have to widen the goal posts or move the End Zone in like the Pig Pharma. Would be so nice to have a level playing field.

[HyGro]

That's funny. Thinking this 700 mg dubious trial result will some how attract any BP. The 700 mg. didn't do better than the 350 mg. which was only 16-20% fat reduction -- which is miserable compared to the other leading NASH candidates that delivered 45%+ fat reduction. LL isn't even close. Not enough to justify an expensive and long Ph3 trial. And clearly not enough for any BP to be interested in a mediocre NASH candidate.

[ClosetInvestor]

Remember, this “great” data is the same data that NP sent to 1,000 BPs 6 months ago. I’d assume BP would’ve jumped on this quickly 6 if a big partnership or buyout was warranted.

https://www.businesswire.com/news/home/20220105005661/en/Leronlimab-14-Week-NASH-Clinical-Trial-Met-Primary-Endpoint-PDFF-and-Secondary-Endpoint-cT1-for-Per-Protocol-Population-in-350-mg-Weekly-Dose

Also recall that a CCR5 inhibitor, cenicriviroc, failed a large NASH trial earlier this year. That was a costly failure as the trail needed to enroll 1778 patients, required biopsies and followed the patients up to 42 months.

https://clinicaltrials.gov/ct2/show/NCT03028740

Cenicriviroc’s failure doesn’t equate to a pending leronlimab NASH failure, but partners may be hesitant to throw large sums of money at the trial as we’ve seen in the previous years